Key Takeaways Bayer has filed an NDA with the FDA for gadoquatrane, a low-dose gadolinium MRI contrast agent. Gadoquatrane cuts gadolinium dose by about 60% compared to current macrocyclic GBCAs. QUANTI studies showed gadoquatrane improves image quality with no new safety concerns in adults or children.Bayer (BAYRY) announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in c ...

Key Takeaways GE HealthCare launched the bkActiv S Series for image-guided, non-surgical urology and pelvic procedures. GEHC's bkActiv S Series offers AI tools, TruSense tech, and single-handed controls for clinician efficiency. GEHC aims to grow recurring revenue through transducer sales, service contracts, and software upgrades.GE HealthCare Technologies Inc. (GEHC) recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound so ...

Core Insights - Klotho Neurosciences, Inc. has terminated its Share Exchange Agreement with SkyBell Technologies, allowing the company to focus on its core R&D programs and enhance shareholder value [2][3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company specializing in innovative, disease-modifying cell and gene therapies derived from the anti-aging human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [4] Strategic Implications - The termination of the agreement eliminates the need to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of Klotho, thereby preventing significant dilution of existing shareholders [7] - The company will not incur any liability as a result of this termination, allowing it to refocus its strategy and allocate resources towards advancing its primary therapeutic and longevity programs [7]

We all wear a mask. Some of us just wear so many we forget our real face. Let me show you mine.Who is it. Come in. Hey, Mommy's Princess.Yes, you can get a snack. Close mommy door behind you. Glow is not just another girls organization.We are the organization. So, if we're really going to make the impact that we say we're making, there must be measurements. You let me know when it's done.Yes, bae. No, I do not know where your glasses are. I'll be done in a minute, baby.Just like the different masks you've j ...

Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting t ...

FORT WORTH, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- Brandon Sisson, CEO of Redacted Optics, today issued the following statement to shareholders following the formal transition of VNUE, Inc. (OTC: VNUE) operations and assets: “It’s hard to put into words the work, sacrifice, and belief it has taken to build this company. What started as a focused mission to innovate the optics space has grown into something far greater—something with the potential to reshape how defense, law enforcement, and sportsmen ope ...

Core Insights - Quantum BioPharma Ltd. has initiated a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis (MS) patients [1][2] - The study utilizes the PET tracer [F]3F4AP, which has shown high sensitivity to demyelinated lesions and favorable pharmacokinetics in previous studies, indicating its potential as a biomarker for monitoring demyelination [1][3] - The new combined GE Signa PET-MR scanner at MGH enhances the imaging process by allowing simultaneous acquisition of PET and MRI signals, improving the accuracy of monitoring demyelination over time [2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in MS [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

ProMIS Neurosciences (PMN) FY Conference June 17, 2025 07:00 AM ET Speaker0 Hello everyone and welcome to this latest series of fireside chats here at the Perspectives on Neurology mini conference hosted by H. C. Wainwright. My name is Ram Selvaraju and I'm a Managing Director and Senior Healthcare Equity Research Analyst here within Wainwright's Equity Research Department. I'm joined here today by Neil Warmah, Chief Executive Officer of Promise Neurosciences, a publicly traded biotechnology company focusin ...

Core Insights - The RealReal has successfully paid off the remaining $26,749,000 of its 3% Convertible Senior Notes due 2025, marking a significant step in reducing its overall debt [1][2] - The company has reduced its total indebtedness by $63 million year to date and $81 million over the last 16 months, indicating a strong focus on deleveraging [1][2] - The CFO highlighted that the paydown enhances financial flexibility and supports strategic growth initiatives, reinforcing the company's position in the luxury resale market [2] Company Overview - The RealReal is the largest online marketplace for authenticated resale luxury goods, boasting over 38 million members [3] - The company employs a rigorous authentication process with hundreds of in-house experts to ensure the reliability of its platform for buying and selling luxury items [3] - The RealReal promotes sustainability by supporting the circular economy, offering services such as free virtual appointments, in-home pickups, and direct shipping for consignors [3]

Core Insights - SkyWater Technology's Wafer Services revenues experienced a 25% year-over-year decline in Q1 FY25 due to decreased demand from automotive customers, but a strong sequential rebound of 70% to $7.5 million was driven by the launch of the ThermaView platform [2][9] - ThermaView, SkyWater's first internally developed product platform for thermal imaging, is already being deployed by two major U.S. defense contractors, indicating its significance in mission-critical applications [3][9] - The company anticipates that ThermaView will be a key growth driver for Wafer Services through FY25, addressing a projected $9 billion market opportunity by 2027 [4][5] Financial Performance - For Q2 FY25, SkyWater expects Wafer Services revenues to be between $5 million and $6 million, reflecting ongoing demand for ThermaView [4][9] - SkyWater's shares have declined by 40.6% year-to-date, contrasting with the Zacks Electronics – Semiconductors industry's return of 3.9% [8] - The current forward 12-month price-to-sales ratio for SkyWater is 1.17, significantly lower than the industry average of 8X, making it an attractive option for value investors [10] Earnings Estimates - The Zacks Consensus Estimate for SkyWater's 2025 loss is currently at 1 cent per share, which has narrowed by 85.7% over the past 60 days, indicating a year-over-year decline of 116.67% [11] - Earnings estimates for the upcoming quarters show a projected loss of $0.17 for the current quarter, a profit of $0.09 for the next quarter, and a loss of $0.01 for the current year [12] Competitive Landscape - SkyWater faces significant competition from GlobalFoundries, which offers a wide range of process technologies and serves diverse markets, holding advantages in scale and capacity [6] - Tower Semiconductor specializes in analog, RF, and MEMS technologies, targeting high-value niches and offering customizable solutions, which positions it as a strong competitor in complex analog projects [7]